Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by EMA

By: Benzinga
Bristol-Myers Squibb (NYSE: BMY ) today announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) for the use of daclatasvir (DCV),
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.